Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

Personalized Cancer Treatment for Ovarian Cancer

“…Given that the platinum-sensitive recurrent ovarian cancers responses to 2 nd line chemotherapy in 47.2-61.7% (Bolis et al, 2001;Cantu et al, 2002;Parmar et al, 2003;Pfisterer et al, 2006) and platinum-refractory responses in only 6.1-25.7% (ten Bokkel et al, 1997;Gordon et al, 2001;Rosenberg et al, 2002;Berkenblit et al, 2004Cannistra et al 2007Mutch et al, 2007), this group of patients treated at Burzynski's Clinic should response in 6.1-25.7%, similar to platinum-refractory cases. Surprisingly, they responded in 42.42%.…”

“…When recur, the (OR) ranges from 47.2-61.7% by various combination chemotherapies: [carboplatinepidoxorubicin (Bolis et al, 2001), cyclophosphamidedoxorubicin-cisplatin (Cantu et al, 2002), carboplatinpaclitaxel (Parmar et al, 2003), and carboplatingemcitabine (Pfisterer et al, 2006)] for platinum sensitive diseases. Markedly lower OR of 6.1-25.7% was reported with single agent chemotherapies: [topotecan (ten Bokkel et al, 1997), pegylated liposomal doxorubicin (Gordon et al, 2001), weekly paclitaxel (Rosenberg et al, 2002), docetaxel (Berkenblit et al, 2004), gemcitabine (Mutch et al, 2007), and bevacizumab (Cannistra et al.…”

Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine

“…Platinum sensitive (> 6) [30] Carboplatin + epirubicin 190 Carboplatin Powered for response differences; OS 17 vs 15 Platinum sensitive ( ‡ 12) [31] Cisplatin + doxorubicin + cyclophosphamide 97 Paclitaxel PFS 15.7 vs 9; OS 34.7 vs 25.8 Platinum sensitive (> 6) [32] Carboplatin + gemcitabine 356 Carboplatin PFS 8.6 vs 5.8; OS 18 vs 17 Platinum sensitive [29] Carboplatin + gemcitabine + placebo 484 Carboplatin + gemcitabine + bevacizumab HR PFS: 0.48 (95% CI 39.0 --61.9%, p < 0.0001) Platinum sensitive (> 6) [33] Cisplatin or carboplatin + paclitaxel 802 Single or non-taxane + platinums PFS 11 vs 9; OS 24 vs 19…”

Management of Recurrent or Persistent Ovarian Cancer

“…The combination of Carboplatin and pegylated-liposomal doxorubicin have resulted in a median PFS of 9 months and a median OS of 31 months (Ferrero et al, 2007). The combination of Carboplatin and Epirubicin versus Carboplatin produced a very limited difference in OS 17 versus 15 months (Bolis et al, 2001). A triple combination of Cisplatin, doxorubicin and cyclophosphamide (CAP) that has been used in the past as first-line treatment of choice versus paclitaxel revealed a significant difference in both PFS 15.7 versus 9 months and in OS 34.7 versus 25.8 months (Cantù et al, 2002).…”